

76706_Auto_Edited.docx

WORD COUNT

3336

TIME SUBMITTED

17-JUL-2022 04:48PM

PAPER ID

88487077

Name of Journal: *World Journal of Virology*

Manuscript NO: 76706

Manuscript Type: MINIREVIEWS

DPP-4 inhibitors in COVID-19: Beyond the glyceic control

Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan

Abstract

12

Coronavirus disease 2019 (COVID-19) is associated with high risk of mortality and complications in patients with diabetes mellitus (DM). Achieving good glyceic control along with reducing complications and mortality due to COVID 19 is very important in diabetes patients. Recent studies have shown mortality benefit and anti-inflammatory effects of Dipeptidyl-peptidase-4 inhibitors (DPP-4i) in diabetes patients with COVID-19 infection. DPP-4i may have a beneficial role in halting the severity of infection primarily by three routes, namely viral entry inhibition, anti-inflammatory and antifibrotic effects and glyceic control. This has raised the promising hypothesis that DPP4-i might be an optimal strategy for treating COVID-19 infection for patients with diabetes. This review aims to summarise the possible therapeutic non-glyceic effects of DPP-4i in diabetes patients diagnosed with COVID-19 in the light of available evidence.

INTRODUCTION

The current Coronavirus Disease 2019 (COVID-19) pandemic is caused by a novel beta coronavirus known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is similar to SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV).^[1] Since late 2019, the disease has spread rapidly worldwide, posing a significant threat to public health. Till date more than 539 million patients are infected across the globe leading to over 6.32 million deaths.^[2] The overall mortality rate for

COVID-19 ranges from 0.7 percent to 10.8 percent.^[3] Nearly two-thirds of severely affected individuals have co-existent comorbidity, most commonly cardiometabolic disorders, with DM accounting for 17% of cases.^[4]

Although DM is not associated with an increased risk of COVID-19 infection, it confers a high risk of rapid progression in the severity of the infection and hence a poor prognosis. Specifically, people with DM are more prone to invasive mechanical ventilation, intensive care unit (ICU) admission, and the development of organ dysfunction, as compared with patients without diabetes.^[5,6] A recent meta-analysis of 83 eligible studies with 78,874 COVID-19 hospitalized patients found that people with pre-existing DM had a doubling of the risk for severe or critical COVID-19 illness (odds ratio [OR] 2.10, 95% confidence interval [95% CI] 1.71-2.57) and a tripling of the risk for in-hospital mortality (OR 2.68, 95% CI 2.09-3.44).^[7] Putative pathogenetic processes linking COVID-19 and DM include hyperglycemia-mediated immune dysregulation, inflammation, and activation of the renin-angiotensin-aldosterone pathway.^[8]

The increasing spread of the SAR-CoV2 infection and the high morbidity necessitates rapid identification of an effective therapy. While developing novel therapies (such as antivirals and vaccines) is a priority, repurposing "old" medications or reconsidering previously well-characterized targets with an emerging function in COVID-19 is the need of the hour. Dipeptidyl peptidase 4 (DPP-4), also known as cluster of differentiation 26 (CD26), has been recently suggested as a potential target receptor for the COVID-19 virus.^[8,9] MERS-CoV, a beta coronavirus similar to SARS-CoV-2, uses DPP-4 as an entrance receptor. Due to its similarity with the MERS-CoV, it has also been proposed that DPP-4 may aid SARS-CoV-2 entry into target cells.^[10] In this context, DPP-4i have gained increasing interest as a therapeutic target in patients with COVID-19.

DPP-4 is a 110 kDa glycoprotein, a membrane-bound endopeptidase that cleaves many peptide hormones such as cytokines, growth factors, and incretin hormones like glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP).^[11] Also, DPP-4 interacts with cellular proteins such as adenosine deaminase (ADA) and caveolin-1 to

regulate immune responses.^[12] DPP-4 exists in two forms in the body, a membrane-bound form or as a soluble form (sDPP-4).^[13] The extracellular portion of DPP-4 is cleaved from cell membranes to form the 727 amino acid soluble moiety sDPP-4, which circulates in the plasma with retained enzyme activity. The DPP-4 receptor is found on the surface of nearly every cell and plays a role in immune regulation, signalling, and cell apoptosis. It is widely expressed in many tissues like the kidney, gastrointestinal tract, and lungs. The primary role of DPP-4 is to regulate in the glucose and insulin metabolism by degradation of incretin hormones such as GLP-1 and GIP. Visceral adipose tissue has greater expression of DPP-4 and it has been linked to adipocyte inflammation and insulin resistance. DPP-4 promotes inflammation in subjects with type 2 diabetes through both catalytic and noncatalytic pathways. DPP-4 directly regulates the immune system by activating T cells and upregulating CD86 expression and the nuclear factor kappa B (NF- κ B) pathway.^[14]

DIPEPTIDYL-PEPTIDASE 4 INHIBITORS

DPP-4i are oral anti-diabetic drugs that affect glucose homeostasis by inhibiting the enzyme DPP-4. DPP-4i prolongs the half-life of incretins by inactivating DPP-4, which cleaves and inactivates them. Incretin hormones GLP-1 and GIP are responsible for the regulation of postprandial insulin.^[15] DPP-4i have been suggested to have cardiovascular benefits. Hence, these medications are commonly used in diabetes patients with a history of cardiovascular or chronic renal disease.^[16] They achieve reasonable glycemic control with no significant effect on body weight, no risk of hypoglycemic events, and reduced cardiovascular mortality and risk. They also have shown a favorable effect on surrogate vascular markers, such as lipid profile, blood pressure, and endothelial function.^[13]

PROPOSED MECHANISMS OF DPP-4I IN COVID

DPP-4i can effectively control blood glucose levels with a favorable safety profile. Good glycemic control can improve the prognosis and outcome of COVID-19.^[17] Hence, DPP-

4i can influence the clinical outcome in COVID-19 patients through their glycemic effects. The mechanisms by which DPP-4i influence the clinical outcomes in COVID-19 patients with DM beyond their glycemic effect are still under speculation and are detailed below.(**Figure 1 and 2**)

DPP-4 AND SARS-COV-2 INTERACTION

I. ROLE AS AN ALTERNATE CO-RECEPTOR

SARS-CoV-2 binds to specific host receptors on the target cell to facilitate entry into the host cell. The SARS-CoV-2 enters the cell *via* binding of viral spike (S) protein to the angiotensin-converting enzyme 2 (ACE-2) receptor on the surface of the host cell membrane. The binding of the S-protein causes a conformational change to the receptor, which is essential for its activation. This critical step known as priming comprises the cleaving of the spike protein by cellular serine proteases. This step enables viral fusion with the cellular membrane and promotes viral entry into the target cell.^[18] Studies have shown a wide distribution of ACE-2 across human tissues, including the lung, gastrointestinal tract, and kidney. However, the expression of ACE-2 on the alveolar type 2 cells, which is supposed to be the primary target cell of SARS-CoV-2, is markedly low. This has paved interest into a possible role for other co-receptors for viral entry.^[19] In-silico modelling of the SARS-CoV-2 spike protein, predicted to have potential interaction with the DPP-4 in addition to ACE-2.^[20] These models suggest that DPP4 may be a co-receptor for SARS-CoV-2 viral entry. Because DPP-4 is widely expressed in cells and tissues other than the respiratory tract, it may facilitate the spread of SARS-CoV-2 infection to a wider range of tissues.^[10] DPP-4 is the receptor for the MERS-CoV spike protein, which mediates viral entrance into host cells.^[21] Due to the high homology between SARS-CoV-2 and MERS-CoV, DPP-4 may also be an accessory entry receptor for SARS-CoV-2.^[22] The presumed role of DPP-4 as a co-receptor for SARS-CoV-2 is still under study.^[14]

II. CROSS TALK BETWEEN DPP-4 AND ACE-2 RECEPTOR

DPP-4 interacts with several essential proteins for viral processing, including ACE-2, implying a possible cross-talk between the two proteins.^[23] In vivo studies have shown the DPP-4i sitagliptin inhibits ACE activity and reduces angiotensin II levels in rats.^[24] This cross-talk could interfere with the viral surface binding and fusion, thereby affecting the spread of the infection.

III. ROLE OF SOLUBLE DPP-4 (SDPP-4)

The fact that DPP-4 exists in two forms, a soluble form (sDPP-4) and membrane-bound form, adds to the intricacy of DPP-4's role in COVID-19 infection. Previous research has shown that sDPP-4 acts as a decoy receptor for MERS-CoV, preventing viral replication.^[12] The same may be applicable to SARS-CoV-2. sDPP-4 may bind SARS-CoV-2, preventing the virus from attaching to membrane-bound DPP-4 in the host cell, thereby hindering viral spread. A German study has shown a reduced circulating level of sDPP-4 in patients with severe COVID-19 infection.^[25] A similar scenario was reported in MERS-CoV infected patients.^[26] Previous studies have shown that sDPP-4 was significantly lower in older individuals than younger individuals.^[27] Serum levels of sDPP-4 are also altered in various clinical diseases, such as DM, obesity, and metabolic syndrome, and are linked to insulin resistance.^[27,28] This may contribute to the severe presentation of SARS-CoV-2 infection in diabetes, obese, and elderly individuals. With this regard, a recent study has shown a 50–100% rise in the levels of sDPP-4 in mice after exposure to DPP-4i.^[29] Hence, DPP-4i, in addition to interfering with viral entrance, may enhance viral particle sequestration in the circulation by increasing sDPP-4 Levels, limiting viral growth in humans.

B. IMMUNOMODULATORY ROLE OF DPP-4I

Dysregulated inflammation accounts for the severity of COVID-19 infection. The severe presentation is linked to a hyperinflammatory state, characterized by an abnormal increase in circulating levels of pro-inflammatory cytokines such as Interleukin (IL)-1, IL-2, IL-6, Interferon- γ and tumor necrosis factor (TNF), leading to acute respiratory

distress syndrome, disseminated intravascular coagulation, multiorgan failure, and death. There is a significant activation of CD4+ and CD8+ T cells in COVID-19 patients and a skewing of T-cells toward the T-helper 17 functional phenotype.^[30] DPP-4 is found in various cell lines involved in immune control, like Th17 T helper cells, natural killer cells, activated B cells, macrophages, and myeloid cells.^[31] DPP-4 promotes T cell proliferation, NF-kB activation, CD86 expression, and excessive production of inflammatory cytokines, all of which contribute to inflammation. Additionally, GLP-1, which DPP-4 degrades, also possesses anti-inflammatory properties.^[32] DPP-4i reduces pro-inflammatory cytokines and mediators like IL-1, IL-6, C-reactive protein (CRP), and TNF-alpha and thereby mitigates the severity of COVID-19. Many studies have shown that sitagliptin has anti-inflammatory effects in diabetes patients, which leads to an increase in an anti-inflammatory cytokine (IL-10) and a decrease in several pro-inflammatory cytokines, like TNF- alpha.^[13] Therefore, the immunomodulatory effects of DPP-4i may prevent dysregulated inflammation and cytokine storms in COVID-19 patients, thereby reducing the severity of the disease.

C. PLEIOTROPIC EFFECTS OF DPP-4I

DPP-4i confers multiple vasculoprotective effects, which reduces the risk of comorbidities associated with DM, including hypertension, cardiovascular disease, and kidney disease. Insulin resistance, oxidative stress, dyslipidemia, adipose tissue dysfunction, and immune dysfunction may all contribute to endothelial dysfunction and arterial stiffness in DM. Beyond glycemic control, DPP-4i regulates these pathogenic mechanisms through GLP-1-dependent and independent pathways for CVD protection.^[33] DPP-4i has been proven in numerous trials to prevent atherosclerosis, improve endothelial function, and promote wound healing possibly by modulating monocyte/macrophage-mediated responses, reducing the oxidative stress, and decreasing neutrophil recruitment and activity.^[33] As a result, Du *et al* recently proposed DPP-4i as a potential therapy for preventing or treating cardiovascular disease produced either directly or indirectly by the COVID-19-induced cytokine

storm.^[34] Through its immune-modulatory action, DPP-4i has also been useful in obesity-related inflammation, hepatic fibrosis, myocarditis, diabetic nephropathy, and chemotherapy-induced kidney injury in animal research trials.^[31]

DPP-4 inhibition directly reduces lipopolysaccharide-induced lung damage in mice and human lung epithelial cells.^[35] Soare *et al* recently discovered that DPP-4 enhances fibroblast activation by increasing transforming growth factor β (TGF- β), a harbinger of tissue fibrosis. Hence, the inactivation of DPP-4 has significant anti-fibrotic effects, validated in numerous experimental models of pulmonary and skin fibrosis.^[36] Sadikot *et al* have recently claimed that GLP-1 could be a new treatment for acute respiratory distress syndrome, demonstrating that human GLP-1 reduces NF- κ B activation in cultured macrophages and a mouse model of acute lung damage^[37]. All these studies point to a possible anti-fibrotic role for DPP-4i.

OBSERVATIONAL STUDIES:

With the above hypothesis, several observational studies have been performed to investigate the impact of DPP-4is on the clinical outcomes in type 2 diabetes mellitus (T2DM) patients hospitalized for COVID-19. (Table 1)

In a cohort study conducted at the University Hospital of Padova, amongst 403 patients hospitalized for COVID- 19, 85 had DM, and nine were on DPP-4i. DPP-4i users and comparators had no significant difference in ICU admission or death rate.^[38] In a retrospective observational study of 120 patients with diabetes, Chen *et al* found that DPP-4i users and non-users had identical clinical outcomes. Users of the DPP-4i had a non-significantly higher rate of in-hospital death than non-users (OR 1.48,95%CI 0.4-5.53).^[39] Similarly, after propensity score matching, Pérez-Belmonte *et al* found that DPP-4i users were not at higher risk for adverse outcomes like ICU admission, mechanical ventilation, multiorgan dysfunction, or long-term hospital admissions.^[40] In a few other observational studies there was no link between DPP-4i therapy and COVID-19-related mortality^[41-46] and severity^[44,47] .

On the contrary, few observational studies have revealed that DPP-4i has favourable effects on COVID-19-related outcomes. In a case series encompassing 387 patients admitted to a research hospital in Lombardy (Northern Italy) with COVID-19 infection, 90 patients were diabetes and 12.2% were on DPP-4i. After adjusting for confounders, DPP-4i use was associated with a decreased death risk (adjusted hazard ratio (HR) 0.13; 95%CI 0.02-0.92). Furthermore, DPP-4i users required less non-invasive mechanical ventilation, implying that their pneumonia was less severe.^[48]

In a multicentric retrospective observational study conducted in Northern Italy, 169 age and gender-matched subjects treated with sitagliptin plus insulin were compared with a similar number of subjects treated with insulin therapy. Primary outcomes assessed were hospital discharge and death, and secondary outcomes analyzed were ICU admission, the need for mechanical ventilation, and extracorporeal membrane oxygenation. The sitagliptin users had significantly lower mortality (18% vs. 37%, $p < 0.001$) even after adjusting for confounders like age, gender, comorbidities, and ongoing treatment (HR 0.44 ; 95%CI 0.29-0.66). On day 30, a larger percentage of patients treated with sitagliptin was discharged from the hospital than those on conventional therapy (71% vs. 59 %, $p < 0.01$). Compared to usual treatment, sitagliptin was associated with a lower probability of needing mechanical ventilation and ICU admission. At follow-up, patients treated with sitagliptin had significantly lower inflammatory markers such as procalcitonin and CRP and lower mean blood glucose levels during hospitalization.^[49]

Similarly, a Korean database-based retrospective study found that DPP-4i treatment was significantly associated with better clinical outcomes even after adjusting for age, gender, comorbidities, and medications (adjusted OR 0.362, 95%CI 0.135-0.971). The study included 832 subjects with DM, of whom 263 were on DPP-4i.^[50] Similarly, DPP-4i usage was related to a shorter ICU stay in 67 patients with DM admitted with COVID-19 pneumonia in a single centre in Iraq (OR 0.3, 95%CI 0.2-3).^[51]

In the coronavirus disease and diabetes outcome (CORONADO) study, a multicentric prospective observational trial conducted in France, 2796 patients hospitalized for SARS-CoV-2 with DM were assessed. Around 21.6% of the participants were on DPP-4i.

The primary outcome as assessed by the need for mechanical ventilation and/or death within seven days was similar in DPP-4i users compared to nonusers. (OR 0.83; 95%CI 0.67–1.03).^[52] Wong *et al* retrospectively analyzed 1214 T2DM patients with confirmed COVID-19 infection admitted to public hospitals in Hong Kong. They found lower risk for clinical deterioration (OR=0.71, 95%CI 0.54–0.93), hyperinflammatory syndrome (OR=0.56, 95%CI 0.45–0.69) and invasive mechanical ventilation (OR=0.30, 95%CI 0.21–0.42) in DPP-4i users. However, DPP-4i users had no significant in-hospital mortality reduction.^[53]

A retrospective review of 717 COVID-19 patients admitted to a health care centre at Singapore found contradictory results. Patients on DPP-4i ($n = 27$) showed greater odds of ICU admission than those on other glucose-lowering medicines (adjusted relative risk [RR] 5.14, 95%CI 1.5–17.7). Also, patients on DPP-4i were more likely to require mechanical ventilation however, no data on mortality were given.^[54] Similarly, Khunti *et al* in their nationwide observational cohort study from UK analysed HR of COVID-19-related mortality in people prescribed with DPP-4i. DPP-4i users had a HR of 1.07 (95%CI 1.01–1.13) for COVID-19-related mortality.^[55]

The evidence available from observational studies on the link between DPP-4i and DM and COVID-19 outcomes suggests some heterogeneity. These were extensively evaluated in multiple meta-analyses.^[56–62] Bonoro *et al* analyzed seven studies that reported data on mortality. There was no significant difference in death rate between patients treated with DPP-4i and other anti-diabetic medications (RR 0.74, 95%CI 0.47–1.16).^[56] Han *et al* also showed similar results with a statistically non-significant lower mortality (OR 0.95, 95%CI 0.72–1.26) or poor composite outcomes (OR 1.27, 95%CI 0.91–1.77) in diabetic COVID-19 patients.^[57] Similarly, Pal *et al* included nine observational studies of high quality consisting of 7008 COVID-19 patients with DM. A pooled analysis of unadjusted and adjusted data revealed no significant link between DPP-4i usage and mortality. However, subgroup analysis discovered that DPP-4i use in the hospital (rather than before admission) was related to lower mortality. (adjusted OR

0.27, 95%CI 0.13-0.55).^[58] In contrary to the above studies, Nguyen *et al* in their recent metaanalysis linked DPP-4i to a higher mortality risk (OR 1.23, 95%CI 1.07–1.42).^[59]

DPP-4i appears to have a neutral action in COVID-19 infection, but the available studies are still insufficient to draw definitive conclusions. It is worth noting that all of the data are from retrospective observational studies and that most of them were not specifically designed to study the effects of DPP-4i. The discrepancies reported for the connection between DPP-4i and COVID-19 outcomes could be explained by variations in methodology, baseline characteristics, and sample size.

RANDOMIZED CONTROL TRIALS:

Two randomized control trials (RCTs) have evaluated the DPP-4i in patients with diabetes and COVID -19. (Table 2)

Abuhasira *et al* investigated 64 patients who were randomised to receive linagliptin 5 mg PO daily or standard of care medication in an open-label, prospective, multicentre RCT (32 in each group). The time to clinical improvement within 28 days of randomization was the primary outcome measured. Treatment with linagliptin in addition to standard therapy did not enhance time to resolution of symptoms (HR 1.22, 95%CI, 0.70–2.15) or death on day 28 (OR 0.56, 95%CI 0.16–1.93). Furthermore, no differences in any of the secondary outcomes, such as the proportion of patients admitted to an ICU, mechanical ventilation rates, length of hospitalisation, or supplemental oxygen use, were seen between the study groups. However, due to the containment of the COVID-19 epidemic in Israel, the experiment was prematurely terminated, leaving the study underpowered to identify possible differences in the primary result and mortality.^[63]

In a parallel, double-blind RCT, Mendoza *et al* evaluated the efficacy of the combination of linagliptin and insulin on metabolic control and prognosis in hospitalized patients with COVID-19 infection and DM. A total of 73 patients were randomly assigned to either 5 mg linagliptin plus insulin (LI group, $n = 35$) or insulin alone (I group, $n = 38$). The need for assisted mechanical ventilation and mortality were the two primary

outcomes. Secondary outcomes were glucose levels and insulin requirements during the first 5–10 days in the hospital, pulmonary parameters, and clinical progression of COVID-19. Both groups had similar average hospital stays (12 ± 1 vs. 10 ± 1 days, $P = 0.343$). Three patients in the LI group and twelve in the I group needed assisted mechanical ventilation (HR 0.258, 95% CI 0.092–0.719), and two patients in the LI group and six in the I group died after a 30-day follow-up ($P = 0.139$). The inclusion of linagliptin reduced the relative risk of assisted mechanical ventilation by 74% and improved pre- and postprandial glucose levels, requiring less insulin and posing no increased risk of hypoglycemia.^[64]

CONCLUSION

Beyond their well-known glycemic role, DPP-4i have anti-inflammatory, immunomodulatory, and anti-fibrotic properties. They are among the non-insulin glucose-lowering medications that are safe and effective in treating T2DM, even in COVID-19, without increasing the risk of significant side events such as hypoglycemia. As a result, practical recommendations for the management of diabetes in patients with COVID-19 do not propose stopping DPP-4i. Even though results from observational studies and a few RCTs have been inconsistent, the existing evidence suggests that DPP-4is is safe for patients with T2DM and COVID-19. Studies showed a trend towards reducing mortality in COVID-19 patients with DM, especially with continued in-hospital use of DPP-4i. As a result, it is appropriate to start or continue DPP-4i in COVID-19 individuals with DM unless contraindicated.

15%

SIMILARITY INDEX

PRIMARY SOURCES

1	Rodolfo Guardado-Mendoza, Miguel Angel Garcia-Magaña, Liz Jovanna Martínez-Navarro, Hilda Elizabeth Macías-Cervantes et al. "Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection", Scientific Reports Internet	117 words — 3%
2	link.springer.com Internet	115 words — 3%
3	www.esp.org Internet	49 words — 1%
4	Marcelo Maia Pinheiro, Andrea Fabbri, Marco Infante. "Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)", Immunotherapy, 2021 Crossref	39 words — 1%
5	www.pubfacts.com Internet	27 words — 1%
6	mtodjournal.net Internet	25 words — 1%
7	bsdwebstorage.blob.core.windows.net Internet	24 words — 1%

- 8 Ran Abuhasira, Irit Ayalon-Dangur, Neta Zaslavsky, Ronit Koren, Mally Keller, Dror Dicker, Alon Grossman. "A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19", *Frontiers in Endocrinology*
Internet 21 words — 1%
-
- 9 www.science.gov
Internet 19 words — 1%
-
- 10 André J. Scheen. "DPP-4 inhibition and COVID-19: From initial concerns to recent expectations", *Diabetes & Metabolism*, 2021
Crossref 18 words — < 1%
-
- 11 www.tandfonline.com
Internet 16 words — < 1%
-
- 12 Www.Medrxiv.Org
Internet 15 words — < 1%
-
- 13 cyberleninka.org
Internet 14 words — < 1%
-
- 14 hashimotoshealing.com
Internet 14 words — < 1%
-
- 15 Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok et al. "Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong", *Diabetes & Metabolism*, 2022
Crossref 13 words — < 1%
-
- 16 Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay 13 words — < 1%

K. Bhadada. "Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis", *Therapeutic Advances in Endocrinology and Metabolism*, 2021

Crossref

17 dspace.zsmu.edu.ua 13 words — < 1%
Internet

18 www.scilit.net 13 words — < 1%
Internet

EXCLUDE QUOTES ON

EXCLUDE SOURCES OFF

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES < 12 WORDS